12:54 CET
E³ 219 - Early detection of prostate cancer
Oncologic Imaging Genitourinary Evidence-Based Imaging
Wednesday, February 27, 10:30 - 12:00
Type of session: E³ - ECR Academies: Hot Topics in GU Cancer
Topic: Oncologic Imaging, Genitourinary, Evidence-Based Imaging
Moderator: G. M. Villeirs (Ghent/BE)

10:30
Chairperson's introduction
G. M. Villeirs; Ghent/BE
Abstract

Prostate cancer is traditionally diagnosed on the basis of the combination of elevated PSA, abnormal digital rectal examination and transrectal biopsy. New biomarkers, including imaging, are currently challenging this gold standard diagnostic test. They are equally useful in the choice between immediate versus deferred treatment. Both aspects will be covered in detail during this session.

10:36
A. Screening for prostate cancer: where are we now? (part 1)
A. George; London/GB
Learning Objectives

1. To be aware of important prostate cancer genetics and familial cancer.
2. To learn about the difference in low risk vs high risk genetic groups.
3. To be aware of the use of imaging and other biomarkers.

10:50
A. Screening for prostate cancer: where are we now? (part 2)
A. Sohaib; London/GB
Learning Objectives

1. To be aware of important prostate cancer genetics and familial cancer.
2. To learn about the difference in low risk vs high risk genetic groups.
3. To be aware of the use of imaging and other biomarkers.

11:04
B. Pre-biopsy detection and new techniques for detection in prostate cancer
S. Punwani; London/GB
Learning Objectives

1. To understand the role of mpMRI in tumour detection.
2. To be aware of texture features of prostate cancer.
3. To learn how texture analysis differentiate benign from malignancy prostate lesions.

11:32
C. Active surveillance: best practice
J. J. Fütterer; Nijmegen/NL
Learning Objectives

1. To be familiar with case selection for active surveillance.
2. To know the frequency of imaging.
3. To understand when treatment will be commenced.

Abstract

In order to avoid unnecessary radical treatment, active surveillance (AS) is becoming a viable treatment alternative in low-risk prostate cancer. Because most low-risk prostate tumours have an indolent course and the slow growth rate allows ample time during follow-up to detect tumours that begin more aggressive while remaining in a window of definitive curability. Patients are carefully observed every three or four months for changes in PSA, digital rectal examination or changes upon performed transrectal ultrasound (TRUS) guided biopsy. MR imaging is an appealing imaging technique to select and to surveil patients who choose for active surveillance. The addition of prostate MR imaging to the biopsy strategy or, in select patients, using MR imaging as a substitute for a repeat biopsy improves prostate cancer detection.

This website uses cookies. Learn more